所有者依赖限制了提供商集团能接受的价值导向合同规模，否则会成为排期问题，而解决方法遵循固定顺序。 对医疗服务提供商而言更难的原因在于结构：在38,000人身上已承担下行风险，却缺乏定价所需的每次发作成本数据。因此任何可信的答案都必须同时掌握每次发作成本和支付方组合，而这正是大多数内部分析停滞的地方，因为两者存在于不同系统中。
所有者依赖限制了提供商集团能接受的价值导向合同规模，否则会成为排期问题，而解决方法遵循固定顺序。 对医疗服务提供商而言更难的原因在于结构：在38,000人身上已承担下行风险，却缺乏定价所需的每次发作成本数据。因此任何可信的答案都必须同时掌握每次发作成本和支付方组合，而这正是大多数内部分析停滞的地方，因为两者存在于不同系统中。
提供商集团最初将所有归属人头绑定在创始临床医生身上；可衡量的问题是这种绑定是否随时间松动。有三层需要依次拆解：归属人头的关系依赖、每次发作成本和支付方组合选择上的决策依赖，以及这些数字生成方式的知识依赖。
归属人头最先移动，因为需要多个合同周期才能让患者群体将集团而非单个临床医生视为责任方。决策规则随后跟进，包括把仅在对话中使用的每次发作成本阈值和支付方组合目标写下来。知识转移最后进行，相当于在原始临床医生不在场的情况下让底层发作成本数据可见。
常见错误是先建立每次发作成本报告，而同一临床医生仍掌握所有关键关系和所有实质决策；结果是形成了一套书面运营，但归属人头和支付方组合选择仍需那一个人。
在此情境下，医务主任仍参与每一次高成本发作审查和每一次新的价值导向谈判。这是关系依赖，体现在每位提供商的贡献数字中，而非缺少数据仪表盘。顺序保持不变：先转移归属人头，再把决策规则写下来。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 面板规模、支付方组合或发作成本目标的每一次实质性变动，都需同一人批准。
✓ 价值导向合同下的归属人头中，有可衡量的比例会在创始临床医生离职后流失。
✓ 任何脱离日常运营的时段，都会停止新的价值导向合同讨论并推迟支付方组合调整。
通常会让情况更糟的做法。 在每次发作成本和支付方组合规则明确之前就聘请第二位医务主任或运营负责人，将新聘者置于未定义的决策环境中。
It is for you if you run or finance a healthcare provider and meaningful decisions wait for one person. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗服务提供商. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Customer Value Architecture · sample company profile
The move. Turn $6.8 M downside-risk liability into a $22–35 M licensing platform within 36 months.
The leak it closes. Eliminates $6.8 M downside exposure by enabling proactive utilization management.
The assumption it rests on. Cost-measurement platform achieves <5 % variance versus manual abstraction within 12 months — the engine put the probability at 0.75.
| Investment required | $2.1–3.5 M over 36 months |
| Expected return | 6.3–16.7× cash-on-cash within 36 months based on $196 M current revenue base. |
| Revenue, year 1 | $0 licensing revenue; $1.8 M internal cost avoidance |
| Revenue, year 2 | $4.2 M licensing ARR (40 physicians × $120K + 5 external practices × $400K) |
| Revenue, year 3 | $13.5 M licensing ARR (90 physicians × $120K + 18 external practices × $400K) plus $4–8 M shared-savings upside |
| Exit criteria | Terminate platform investment if variance exceeds 8 % by Month 18 OR if fewer than 40 physicians sign licensing agreements by Month 24; redeploy remaining capital to ASC surgeon-retention track. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Organizational Alignment Model, one of 29 engagements the platform runs. For 医疗服务提供商 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
先转移关系，再转移决策，最后转移知识。顺序重要，因为关系转移耗时最长，在任何出售中价值也最高。
影响很大，通过倍数而非收益实现。买家为离开你后仍能存续的部分定价，因此依赖你的利润会被大幅折价或剔除。
等他们将负责的决策先被明确之后再聘请。聘请一人来厘清这些决策，通常结果是所有者仍做那份工作，却为此多付了一次钱。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית